DE69130445T2 - Die Mac-1-Bindungsstelle von ICAM-1 - Google Patents

Die Mac-1-Bindungsstelle von ICAM-1

Info

Publication number
DE69130445T2
DE69130445T2 DE69130445T DE69130445T DE69130445T2 DE 69130445 T2 DE69130445 T2 DE 69130445T2 DE 69130445 T DE69130445 T DE 69130445T DE 69130445 T DE69130445 T DE 69130445T DE 69130445 T2 DE69130445 T2 DE 69130445T2
Authority
DE
Germany
Prior art keywords
icam
mac
binding site
relates
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69130445T
Other languages
English (en)
Other versions
DE69130445D1 (de
Inventor
Michael S Diamond
Donald E Staunton
Timothy A Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BLOOD RES CENTER
Original Assignee
BLOOD RES CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BLOOD RES CENTER filed Critical BLOOD RES CENTER
Application granted granted Critical
Publication of DE69130445D1 publication Critical patent/DE69130445D1/de
Publication of DE69130445T2 publication Critical patent/DE69130445T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ropes Or Cables (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Package Frames And Binding Bands (AREA)
  • Hall/Mr Elements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69130445T 1990-11-28 1991-11-21 Die Mac-1-Bindungsstelle von ICAM-1 Expired - Fee Related DE69130445T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/618,286 US5288854A (en) 1990-11-28 1990-11-28 Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1

Publications (2)

Publication Number Publication Date
DE69130445D1 DE69130445D1 (de) 1998-12-10
DE69130445T2 true DE69130445T2 (de) 1999-07-08

Family

ID=24477094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130445T Expired - Fee Related DE69130445T2 (de) 1990-11-28 1991-11-21 Die Mac-1-Bindungsstelle von ICAM-1

Country Status (8)

Country Link
US (1) US5288854A (de)
EP (1) EP0488061B1 (de)
KR (1) KR920009412A (de)
AT (1) ATE172988T1 (de)
DE (1) DE69130445T2 (de)
DK (1) DK0488061T3 (de)
ES (1) ES2122964T3 (de)
NZ (2) NZ260473A (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
DE69131564T2 (de) * 1990-07-20 2000-01-13 Bayer Ag Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
CA2144738A1 (en) * 1992-10-09 1994-04-28 Michael Diamond A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
ATE298248T1 (de) * 1998-04-15 2005-07-15 Brigham & Womens Hospital T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
DE60140457D1 (de) * 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
HUP0402305A2 (hu) * 2000-11-28 2005-02-28 Genentech, Inc. LFA-1-antagonista vegyületek, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
PL1682537T3 (pl) * 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
AU2005277547B2 (en) 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
US20060233675A1 (en) * 2005-04-13 2006-10-19 Stein Israel M Glass test tube having protective outer shield
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
US20100008937A1 (en) * 2006-04-25 2010-01-14 Immune Disease Institute, Inc. Targeted delivery to leukocytes using non-protein carriers
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
EP3632444A3 (de) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
EP3897851A2 (de) 2018-12-17 2021-10-27 Revitope Limited Doppelimmunzell-engager

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (de) * 1987-11-02 1994-12-07 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ES2077572T3 (es) * 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.

Also Published As

Publication number Publication date
NZ260473A (en) 1997-06-24
DK0488061T3 (da) 1999-07-19
US5288854A (en) 1994-02-22
EP0488061A2 (de) 1992-06-03
NZ240747A (en) 1996-05-28
EP0488061A3 (en) 1992-08-26
KR920009412A (ko) 1992-06-25
EP0488061B1 (de) 1998-11-04
ES2122964T3 (es) 1999-01-01
DE69130445D1 (de) 1998-12-10
ATE172988T1 (de) 1998-11-15

Similar Documents

Publication Publication Date Title
DE69130445D1 (de) Die Mac-1-Bindungsstelle von ICAM-1
DK0445255T4 (da) Anvendelse af hyaluronsyre i kombination med ascorbinsyre, antitumormidler og/eller NSAID's til behandling af cancer
GR3006073T3 (de)
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DK0745852T3 (da) Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
ES2134762T3 (es) Formas multimericas de proteinas receptoras de rinovirus humanos.
ATE63815T1 (de) Verwendung von zinn-protoporphyrin und zinnmesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE69331105T2 (de) Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen
FI973185A (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DK468885A (da) Middel til topisk behandling af betaendelsestilstande i huden
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
OA08355A (fr) Nouveaux benzamides, leur procédé de préparation et leur application dans le domaine thérapeutique.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
ATE79759T1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
IT7820999A0 (it) Nuovo derivato dell'ajmalina, processo per la sua preparazione, e suo impiego in terapia.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE2999T1 (de) Xanthinderivate und pharmazeutische zusammensetzung zur verwendung fuer die behandlung chronischer verstopfungen der atemwege und von herzkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee